Salsalate
- N02BA06 (WHO)
- US: WARNING[1]Rx-only
- 2-(2-Hydroxybenzoyl)oxybenzoic acid
- 552-94-3 Y
- 5161
- DB01399 Y
- 4977 N
- V9MO595C9I
- D00428 N
- CHEBI:9014 N
- DTXSID1023572
Salsalate is a medication that belongs to the salicylate and nonsteroidal anti-inflammatory drug (NSAID) classes.
Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[2]
Mechanism of action
Relative to other NSAIDs, salsalate has a weak inhibitory effect on the cyclooxygenase enzyme and decreases the production of several proinflammatory chemical signals such as interleukin-6, TNF-alpha, and C-reactive protein.[3]
The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of IκB kinase resulting in decreased action of NF-κB genes.[3][4][5] This mechanism is thought to be responsible for salsalate's insulin-sensitizing and blood sugar lowering properties.[4]
Medical uses
Salsalate may be used for inflammatory disorders such as rheumatoid arthritis or noninflammatory disorders such as osteoarthritis.[3][6]
Safety
The risk of bleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with aspirin use.[4]
Research
Salsalate has been proposed for the prevention and treatment of type 2 diabetes mellitus due to its ability to lower insulin resistance associated with inflammation and may be useful in prediabetes.[3] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[3]
History
Salsalate had been suggested as possible treatment for diabetes as early as 1876.[3][7][8]
Synthesis
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Salsalate". drugs.com.
- ^ a b c d e f Anderson K, Wherle L, Park M, Nelson K, Nguyen L (June 2014). "Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies". American Health & Drug Benefits. 7 (4): 231–5. PMC 4105730. PMID 25126374.
- ^ a b c Esser N, Paquot N, Scheen AJ (March 2015). "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease". Expert Opinion on Investigational Drugs (Review). 24 (3): 283–307. doi:10.1517/13543784.2015.974804. PMID 25345753. S2CID 23674166.
- ^ Ridker PM, Lüscher TF (July 2014). "Anti-inflammatory therapies for cardiovascular disease". European Heart Journal. 35 (27): 1782–91. doi:10.1093/eurheartj/ehu203. PMC 4155455. PMID 24864079.
- ^ Hardie DG (July 2013). "AMPK: a target for drugs and natural products with effects on both diabetes and cancer". Diabetes. 62 (7): 2164–72. doi:10.2337/db13-0368. PMC 3712072. PMID 23801715.
- ^ Powell K (May 2007). "Obesity: the two faces of fat". Nature. 447 (7144): 525–7. Bibcode:2007Natur.447..525P. doi:10.1038/447525a. PMID 17538594. S2CID 28974642.
- ^ Ebstein W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift. 13: 337–340.
- ^ Cavallito CJ, Buck JS (1943). "Synthesis of Phenolic Acid Esters. I. Depsides1". Journal of the American Chemical Society. 65 (11): 2140–2142. doi:10.1021/ja01251a034.
- ^ Baker W, Ollis WD, Zealley TS (1951). "42. Eight- and higher-membered ring compounds. Part II. Di-, tri-, tetra-, and hexa-salicylides". Journal of the Chemical Society (Resumed): 201. doi:10.1039/JR9510000201.
- ^ DE 211403, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure aus Salicylsäure oder ihrne Salzen [Process for preparing a crystallized salicylosalicylic acid from salicylic acid or its salts]", published 1909-06-25, assigned to C.F. Boehringer & Söhne
- ^ DE 214044, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure [Process for preparing a crystallized salicylosalicylic acid]", published 1909-09-20, assigned to C.F. Boehringer & Söhne
- v
- t
- e
pyrazolidines
and related substances
- Ampiroxicam
- Droxicam
- Isoxicam
- Lornoxicam
- Meloxicam
- Piroxicam
- Pivoxicam
- Tenoxicam
derivatives (profens)
- Alminoprofen
- Benoxaprofen†
- Carprofen‡
- Dexibuprofen
- Dexketoprofen
- Fenbufen
- Fenoprofen
- Flunoxaprofen
- Flurbiprofen
- Ibuprofen#
- Ibuproxam
- Indoprofen†
- Ketoprofen
- Loxoprofen
- Miroprofen
- Naproxen
- Oxaprozin
- Pelubiprofen
- Piketoprofen
- Pirprofen
- Suprofen
- Tarenflurbil
- Tepoxalin‡
- Tiaprofenic acid
- Vedaprofen‡
- Zaltoprofen
- COX-inhibiting nitric oxide donator: Naproxcinod
acids (fenamates)
(coxibs)
combinations
- category
- commons
- portal
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e